Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder

BJU International

Volumn 106, Issue 2, 2010, Pages 268-274

  Andersson, Karl Erik ^a   Sarawate, Chaitanya ^b   Kahler, Kristijan H ^c   Stanley, Elizabeth L ^c   Kulkarni, Amit S ^c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b HEALTHCORE INC   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

antimuscarinic; cardiovascular comorbidities; OAB; overactive bladder

Indexed keywords

DARIFENACIN; FESOTERODINE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PROPIVERINE; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

ADULT; AGED; ANTICHOLINERGIC EFFECT; ARTICLE; BLADDER DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMORBIDITY; DATA BASE; DRUG EXPOSURE; FEMALE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERACTIVE BLADDER; PREVALENCE; PRIORITY JOURNAL; SIDE EFFECT;

AGED; CARDIOVASCULAR DISEASES; EPIDEMIOLOGIC METHODS; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; UNITED STATES; URINARY BLADDER, OVERACTIVE;

EID: 77953818082     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09073.x     Document Type: Article

References (31)

1. Abrams P, Cardozo L, Fall M et al. Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002 21 : 167 178
2. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001 87 : 760 766
3. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 20 : 327 336
4. Corcos J, Schick E. Prevalence of overactive bladder and incontinence in Canada. Can J Urol 2004 11 : 2278 2284
5. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006 50 : 1306 1314
6. Homma Y, Yamaguchi O, Hayashi K. An epidemiological survey of overactive bladder symptoms in Japan. BJU Int 2005 96 : 1314 1318
7. Temml C, Heidler S, Ponholzer A, Madersbacher S. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur Urol 2005 48 : 622 627
8. Choi JB, Kim YB, Kim BT, Kim YS. Analysis of heart rate variability in female patients with overactive bladder. Urology 2005 65 : 1109 1112
9. Hubeaux K, Deffieux X, Ismael SS, Raibaut P, Amarenco G. Autonomic nervous system activity during bladder filling assessed by heart rate variability analysis in women with idiopathic overactive bladder syndrome or stress urinary incontinence. J Urol 2007 178 : 2483 2487
10. La Rovere MT, Pinna Hohnloser GD, Marcus SH et al. Autonomic Tone and Reflexes After Myocardial Infarcton. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation 2001 103 : 2072 2077
11. La Rovere MT, Bigger JT Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998 351 : 478 484
12. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetière P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005 352 : 1951 1958 (Pubitemid 40638365)
13. Andersson KE, Olshansky B. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int 2007 100 : 1007 1014
14. Sniderman AD, Furberg CD. Age as a modifiable risk factor for cardiovascular disease. Lancet 2008 371 : 1547 1549
15. Jouven X, Empana JP, Escolano S et al. Relation of heart rate at rest and long-term (>20 years) death rate in initially healthy middle-aged men. Am J Cardiol 2009 103 : 279 283
16. Hsia J, Larson JC, Ockene JK et al. Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study. BMJ 2009 338 : b219
17. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003 163 : 2716 2724
18. Wilhelmsen L, Berglund G, Elmfeldt D, Samuelsson O, Svardsudd K. The multifactor primary prevention trial in Goteborg. Sweden Eur Heart J 1986 7 : 279 288
19. Coyne KS, Kaplan Chapple SA, Sexton CR et al. Risk factors and comorbid conditions associated with lower urinary tract symptoms. EpiLuts. BJU Int 2009 103 (Suppl. 3 24 32
20. Stevens LA, Chapple CR, Chess-Williams R. Human idiopathic and neurogenic overactive bladders and the role of M2 muscarinic receptors in contraction. Eur Urol 2007 52 : 531 538
21. Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999 51 : 651 690
22. Abrams P, Andersson KE, Buccafusco JJ et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006 148 : 565 578
23. Kannel WB, Kannel C, Paffenbarger RS Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987 113 : 1489 1494
24. Mensink GB, Hoffmeister H. The relationship between resting heart rate and all-cause, cardiovascular and cancer mortality. Eur Heart J 1997 18 : 1404 1410
25. Fox K, Borer JS, Camm AJ et al. Heart Rate Working Group. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007 50 : 823 830
26. Aronow WS, Ahn C, Mercando AD, Epstein S. Association of average heart rate on 24-hour ambulatory electrocardiograms with incidence of new coronary events at 48-month follow-up in 1,311 patients (mean age 81 years) with heart disease and sinus rhythm. Am J Cardiol 1996 78 : 1175 1176
27. Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med 2000 93 : 457 462
28. Kay GG, Abou-Donia MB, Messer WS Murphy DG, Tsao JW, Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005 53 : 2195 2201
29. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008 300 : 1439 1450
30. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007 100 : 987 1006
31. Olshansky B, Ebinger U, Brum J, Egermark M, Viegas A, Rekeda L. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants ≥ 50 years. J Cardiovasc Pharmacol Ther 2008 13 : 241 251